Podcasts about oncologists

Oncologist and health care executive Yousuf Zafar discusses his article, "When cancer costs too much: Why financial toxicity deserves a place in clinical conversations." Yousuf explains the concept of "financial toxicity," a severe burden caused by both direct medical bills and indirect costs (like time off work or child care) associated with cancer treatment. He reveals the sobering statistic that over forty percent of patients deplete their savings within two years, but emphasizes that this distress is more than just a financial problem: it directly compromises treatment adherence, forcing some to skip appointments or forgo prescriptions. Yousuf highlights the critical lack of cost transparency in oncology and makes the case for why clinicians must proactively screen for financial strain just as they would for physical side effects. Discover why these difficult conversations about the cost of cancer are essential for improving patient outcomes and quality of life. Our presenting sponsor is Microsoft Dragon Copilot. Want to streamline your clinical documentation and take advantage of customizations that put you in control? What about the ability to surface information right at the point of care or automate tasks with just a click? Now, you can. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Offering an extensible AI workspace and a single, integrated platform, Dragon Copilot can help you unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise, and it's part of Microsoft Cloud for Healthcare, built on a foundation of trust. Ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Dr. Monty Pal and Dr. Jason Westin discuss the federal funding climate for cancer research and the persistent problem of drug shortages, two of the major concerns facing the oncology community in 2026. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. There are always multiple challenges facing oncologists, and today, we discuss two of them that really stand out for 2026: threats to federal funding for cancer research and the persistent problem of drug shortages. I am thrilled to welcome Dr. Jason Westin, who believes that one way to meet these challenges is to get oncologists more involved in advocacy, and he will share some strategies to help us meet this moment in oncology. Dr. Westin is a professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, but he actually wears a lot of hats within ASCO. He is a member of the Board of Directors and has also previously served as chair of ASCO's Government Relations Committee. And he is also one of the inaugural members of ASCO's Political Action Committee, or PAC. He has testified before Congress about drug shortages and many other issues. Dr. Westin, I am really excited to have you on the podcast today and dive into some of these elements that will really impact our community in 2026. Thanks so much for joining us today. Dr. Jason Westin: Thank you for having me. Dr. Monty Pal: You've had such a range of experience. I already alluded to you testifying before Congress. You've actually run for office before. You wear so many different hats. I'm used to checking my PubMed every other day and seeing a new paper out from you and your group, and you publish in the New England Journal [of Medicine] on practice-setting standards and the diseases that you treat. But you've also done all this work in the domain of advocacy. I can't imagine that balancing that is easy. What has sort of motivated you on the advocacy front? Dr. Jason Westin: Advocacy to me is another way to apply our skills and help more people than just those that you're sitting across from at the time. Clinical research, of course, is a tool to try and take what we know and apply it more broadly to people that you'll never meet. And advocacy, I think, can do the same thing, where you can have a conversation with a lawmaker, you can advocate for a position, and that hopefully will help thousands or maybe even more people down the road who you'd never get to directly interact with. And so, I think it's a force multiplier in the same way that research can be. And so, I think advocacy is a wonderful part of how doctors care for our patients. And it's something that is often difficult to know where to start, but once people get into advocacy, they can see that the power, the rewarding nature of it is attractive, and most people, once they get going, continue with that through the rest of their career. Dr. Monty Pal: So, I'll ask you to expand on that a little bit. We have a lot of our younger ASCO members listening to this podcast, folks that are just starting out their careers in clinical practice or academia. Where does that journey begin? How do you get to the point that you're testifying in front of Congress and taking on these bigger sort of stances for the oncology community? Dr. Jason Westin: Yeah, with anything in medicine and in our careers, you have to start somewhere. And often you start with baby steps before you get in front of a panel of senators or other high-profile engagement opportunities. But often the first setting for junior colleagues to be engaged is doing things – we call them "Hill Days" – but basically being involved in kind of low-stakes meetings where you're with a group of peers, some of whom have done this multiple times before, and can get engaged talking to members of representatives' offices, and doing so in a way where it's a natural conversation that you're telling a story about a patient in your clinic, or that you're telling a personal experience from a policy that impacted your ability to deliver optimal care. It sounds stressful, but once you're doing it, it's not stressful. It's actually kind of fun. And it's a way that you can get comfort and skill with a group of peers who are there and able to help you. And ASCO has a number of ways to do that, both at the federal level, there's the Hill Day where we each April have several hundred ASCO members travel to Capitol Hill. There's also state engagement that can be done, so-called visiting at home, when representatives from the U.S. Congress or from state legislators are back in district. You can meet with your own representatives on behalf of yourself, on behalf of your organization, and advocate for policies in a way that can be beneficial to your patients. But those initial meetings that are in the office often they're low stakes because you could be meeting not with the representative but with their staff. And that staff sometimes is as young or even younger than our junior colleagues. These sometimes can be people in their 20s, but they're often extremely knowledgeable, extremely approachable, and are used to dealing with people who are new to advocacy. But they actually help make decisions within the office. So it's not a waste of time. It's actually a super useful way to engage. So, it's that first step of anything in life. The activation energy is always high to do something new. But I'd encourage people who are listening to this podcast already having some level of interest about it to explore ways that they could engage more. Dr. Monty Pal: You know, I have to tell you, I'm going to riff on what you just said for a second. ASCO couldn't make it any easier, I think, for folks to participate and get involved. So, if you're listening to this and scratching your head and thinking, "Well, where do I begin? How do I actually sign on for that meeting with a local representative?" Go to the ASCO ACT Network website. And I'll actually talk to our producer, Geraldine, to make sure we've got a link to that somewhere associated with this podcast after it's published, Jason, but I actually keep that on my browser and it's super easy. I check in there every now and then and see if there's any new policy or legislation that ASCO, you know, is sort of taking a stance on, and it gives me some fodder for conversation with my local representatives too. I mean, it's just an awesome, awesome vehicle. I'm going to segue right from there right to the issues. So, you and I are both at academic centers. You know, I think this is something that really pervades academia and enters into implications for general clinical practice. There's been this, you know, massive sort of proposal for decreased funding to the NCI and to the NIH and so forth. Tell us what ASCO is doing in that regard, and tell us perhaps how our community can help. Dr. Jason Westin: We live in interesting times, and I think that may be an understatement x 100. But obviously investments in research are things that when you're at an academic center, you see and feel that as part of your daily life. Members of Congress need to be reminded of that because there's a lot of other competing interests out there besides investing in the future through research. And being an elected representative is a hard job. That is something where you have to make difficult choices to support this, and that may mean not supporting that. And there's lots of good things where our tax dollars could be spent. And so, I'm sympathetic to the idea that there's not unlimited resources. However, ASCO has done an excellent job, and ASCO members have led the charge on this, of stating what research does, what is the benefit of research, and therefore why should this matter to elected representatives, to their staff, and to those people that they're elected to serve. And ASCO has led with a targeted campaign to basically have that message be conveyed at every opportunity to elected representatives. And each year on Hill Day, one of the asks that we have is to continue to support research: the NCI, NIH, ARPA-H, these are things that are always in the asks to make sure that there's appropriate funding. But effectively playing offense by saying, "It's not just a number on a sheet of paper, this is what it means to patients. This is what it means to potentially your loved ones in the future if you are in the opposite situation where you're not on the legislative side, but you're in the office receiving a diagnosis or receiving a difficult piece of news." We only have the tools we have now because of research, and each breakthrough has been years in the making and countless hours spent funded through the engine of innovation: clinical research and translational research. And so ASCO continues to beat that drum. You mentioned earlier the ACT Network. Just to bring that back again is a very useful, very easy tool to communicate to your elected representatives. When you sign up on the ASCO ACT website, you get emails periodically, not too much, but periodically get emails of, "This is a way you can engage with your lawmakers to speak up for this." And as you said, Monty, they make it as easy as possible. You click the button, you type in your address so that it figures out who your elected representatives are, and then it will send a letter on your behalf after like five clicks to say, "I want you to support research. I want you to vote for this particular thing which is of interest to ASCO and by definition to members of ASCO." And so the ACT Network is a way that people listening can engage without having to spend hours and significant time, but just a few clicks can send that letter to a representative in Congress. And the question could be: does that matter? Does contacting your senator or your elected representative do anything? If all they're hearing is somebody else making a different argument and they're hearing over and over again from people that want investments in AI or investments in something else besides cancer research, whatever it is, they may think that there's a ground shift that people want dollars to be spent over here as opposed to at the NIH or NCI or in federally funded research. It is important to continue to express the need for federal funding for our research. And so, it really is important for folks to engage. Dr. Monty Pal: 100%. One of the things that I think is not often obvious to a lot of our listeners is where the support for clinical trials comes from. You know, you've obviously run the whole gamut of studies as have I. You know, we have our pharmaceutical company-sponsored studies, which are in a particular bucket. But I would say that there's a very important and critical subset of studies that are actually government funded, right? NCI-funded clinical trials. If you don't mind, just explain to our audience the critical nature of the work that's being done in those types of studies and if you can, maybe compare and contrast the studies that are done in that bucket versus perhaps the pharmaceutical bucket. Dr. Jason Westin: Both are critical, and we're privileged that we have pharma studies that are sponsored and federally funded clinical research. And I think that part of a healthy ecosystem for us to develop new breakthroughs has a need for both. The pharma sponsored studies are done through the lens of trying to get an approval for an agent that's of interest so that the pharma company can then turn around and use that outside of a clinical trial after an FDA approval. And so those studies are often done through the lens of getting over the finish line by showing some superiority over an existing treatment or in a new patient population. But they're done through that lens of kind of the broadest population and sometimes relatively narrow endpoints, but to get the approval so that then the drug can be widely utilized. Clinical trials done through cooperative groups are sometimes done to try and optimize that or to try and look at comparative things that may not be as attractive to pharma studies, not necessarily going for that initial approval, but the fine tuning or the looking at health outcomes or looking at ensuring that we do studies in representative populations that may not be as well identified on the pharma sponsored trials, but basically filling out the gaps in the knowledge that we didn't gain from the initial phase 3 trial that led to the approval. And so both are critical. But if we only do pharma sponsored trials, if we don't fund federally supported research and that dries up, the fear I have, and many others have, is that we're going to be lacking a lot of knowledge about the best ways to use these great new therapies, these new immune therapies, or in my team, we do a lot of clinical trials on CAR T-cell therapies. If we don't have federally funded research to do the important clinical studies, we'll be in the dark about the best ways to use these drugs, and that's going to be a terrible shame. And so we really do need to continue to support federal research. Dr. Monty Pal: Yeah, there are no softball questions on this podcast, but I think everybody would be hard pressed to think that you and I would come on here and say, "Well, no, we don't need as much money for clinical trials and NCI funding" and so forth. But I think a really challenging issue to tackle, and this is something we thought to ask you ahead of the podcast, is what to do about the general climate of, you know, whether it's academic research or clinical practice here that seems to be getting some of our colleagues thinking about moving elsewhere. I've actually talked to a couple of folks who are picking up and moving to Europe for a variety of considerations, other continents, frankly. The U.S. has always been a leader when it comes to oncology research and, one might argue, research in general. Some have the mindset these days that we're losing that footing a little bit. What's your perspective? Are you concerned about some of the trends that you're seeing? What does your crystal ball tell you? Dr. Jason Westin: I am highly concerned about this. I think as you said, the U.S. has been a leader for a long time, but it wasn't always. This is not something that's preordained that the world-leading clinical research and translational research will always be done in the United States. That is something that has been developed as an ecosystem, as an engine for innovation and for job development, new technology development, since World War II. That's something that through intentional investments in research was developed that the best and brightest around the world, if they could choose to go anywhere, you wanted them to come to work at universities and academic places within the United States. And I think, as you said, that's at risk if you begin to dry up the investment in research or if you begin to have less focus on being engaged in research in a way that is forward thinking, not just kind of maintaining what we do now or only looking at having private, for profit sponsored research. But if you don't have the investment in the basic science research and the translational research and the forward-thinking part of it, the fear is that we lose the advantage and that other countries will say, "Thank you very much," and be happy to invest in ways to their advantage. And I think as you mentioned, there are people that are beginning to look elsewhere. I don't think that it's likely that a significant population of researchers in the U.S. who are established and have careers and families – I don't think that we're going to see a mass exodus of folks. I think the real risk to me is that the younger, up-and-coming people in undergraduate or in graduate school or in medical school and are the future superstars, that they could either choose to go into a different field, so they decide not to go into what could be the latest breakthroughs for cancer patients but could be doing something in AI or something in a different field that could be attractive to them because of less uncertainty about funding streams, or they could take that job offer if it's in a different country. And I think that's the concern is it may not be a 2026 problem, but it could be a 2036 or a 2046 problem that we reap what we sow if we don't invest in the future. Dr. Monty Pal: Indeed, indeed. You know, I've had the pleasure of reviewing abstracts for some of our big international meetings, as I'm sure you've done in the past too. I see this trend where, as before, we would see the preponderance of large phase 3 clinical trials and practice setting studies being done here in the U.S., I'm seeing this emergence of China, of other countries outside of the U.S. really taking lead on these things. And it certainly concerns me. If I had to sort of gauge this particular issue, it's at the top of my list in terms of what I'm concerned about. But I also wanted to ask you, Jason, in terms of the issues that are looming over oncology from an advocacy perspective, what else really sort of keeps you up at night? Dr. Jason Westin: I'm quite concerned about the drug shortages. I think that's something that is a surprisingly evergreen problem. This is something that is on its face illogical that we're talking about the greatest engine for research in the world being the United States and the investment that we've made in drug development and the breakthroughs that have happened for patients all around the world, many of them happen in the United States, and yet we don't necessarily have access to drugs from the 1970s or 1980s that are cheap, generic, sterile, injectable drugs. This is the cisplatins and the vincristines and the fludarabine type medications which are not the sexy ones that you see the ads in the magazine or on TV at night. These are the backbone drugs for many of our curative intent regimens for pediatrics and for heme malignancies and many solid tumors. And the fact that that's continuing to be an issue is, in my opinion, a failure to address the root causes, and those are going to require legislative solutions. The root causes here are basically a race to the bottom where the economics to invest in quality manufacturing really haven't been prioritized. And so it's a race to the cheapest price, which often means you undercut your competitor, and when you don't have the money to invest in good manufacturing processes, the factory breaks down, there's no alternative, you go into shortage. And this has been going on for a couple of decades, and I don't think there's an end in sight until we get a serious solution proposed by our elected officials. That is something that bothers me in the ways where we know what we should be doing for our patients, but if we don't have the drugs, we're left to be creative in ways we shouldn't have to do to figure out a plan B when we've got curative intent therapies. And I think that's a real shame.  There's obviously a lot of other things that are concerning related to oncology, but something that I have personally had experience with when I wanted to give a patient a CAR T-cell, and we don't have a supply of fludarabine, which is a trivial drug from decades ago in terms of the technology investments in genetically modified T-cells, to not then have access to a drug that should be pennies on the dollar and available at any time you want it is almost like the Air Force investing in building the latest stealth bomber, but then forgetting to get the jet fuel in a way that they can't use it because they don't have the tools that they need. And so I think that's something that we do need to have comprehensive solutions from our elected officials. Dr. Monty Pal: Brilliantly stated. I like that analogy a lot. Let's get into the weeds for a second. What would that proposal to Congress look like? What are we trying to put in front of them to help alleviate the drug shortages? Dr. Jason Westin: We could spend a couple hours, and I know podcasts usually are not set up to do that. And so I won't go through every part. I will direct you that there have been a couple of recent publications from ASCO specifically detailing solutions, and there was a recent white paper from the Senate Finance Committee that went through some legislative solutions being explored. So Dr. Gralow, ASCO CMO, and I recently had a publication in JCO OP detailing some solutions, more in that white paper from the Senate Finance. And then there's a working group actually going through ASCO's Health Policy Committee putting together a more detailed proposal that will be published probably around the end of 2026. Very briefly, what needs to happen is for government contracts for purchasing these drugs, there needs to be an outlay for quality, meaning that if you have a manufacturing facility that is able to deliver product on time, reliably, you get a bonus in terms of your contract. And that changes the model to prioritize the quality component of manufacturing. Without that, there's no reason to invest in maintaining your machine or upgrading the technology you have in your manufacturing plant. And so you have bottlenecks emerge because these drugs are cheap, and there's not a profit margin. So you get one factory that makes this key drug, and if that factory hasn't had an upgrade in their machines in 20 years, and that machine conks out and it takes 6 months to repair or replacement, that is an opportunity for that drug to go into shortage and causes a mad dash for big hospitals to purchase the drug that's available, leaving disparities to get amplified. It's a nightmare when those things happen, and they happen all the time. There are usually dozens, if not hundreds, of drugs in shortage at any given time. And this has been going on for decades. This is something that we do need large, system-wide fixes and that investment in quality, I think, will be a key part. Dr. Monty Pal: Yeah, brilliantly said. And I'll make sure that we actually include those articles on the tagline for this podcast as well. I'll talk to our producer about that as well.  I'm really glad you mentioned the time in your last comment there because I felt like we just started, but in fact, I think we're right at our close here, Jason, unfortunately. So, I could have gone on for a couple more hours with you. I really want to thank you for these absolutely terrific insights and thank you for all your advocacy on behalf of ASCO and oncologists at large. Dr. Jason Westin: Thank you so much for having me. I have enjoyed it. Dr. Monty Pal: Thanks a lot. And many thanks to our listeners too. You can find more information about ASCO's advocacy agenda and activities at asco.org. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks so much. ASCO Advocacy Resources: Get involved in ASCO's Advocacy efforts: ASCO Advocacy Toolkit Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions, JCO Oncology Practice Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Monty Pal   @montypal   Dr. Jason Westin @DrJasonWestin   Follow ASCO on social media:      @ASCO on X     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Jason Westin: Consulting or Advisory Role: Novartis, Kite/Gilead, Janssen Scientific Affairs, ADC Therapeutics, Bristol-Myers Squibb/Celgene/Juno, AstraZeneca, Genentech/Roche, Abbvie, MorphoSys/Incyte, Seattle Genetics, Abbvie, Chugai Pharma, Regeneron, Nurix, Genmab, Allogene Therapeutics, Lyell Immunopharma Research Funding: Janssen, Novartis, Bristol-Myers Squibb, AstraZeneca, MorphoSys/Incyte, Genentech/Roche, Allogene Therapeutics

In this episode of Parts and Labor, Angela Chaudhari, MD, hosts a panel of experts from Northwestern Medicine's Division of Gynecologic Oncology to explore the innovative role of robotic surgery in cancer care. The discussion highlights how robotic technology is improving outcomes for patients with gynecologic cancers through minimally invasive techniques, enhanced precision and interdisciplinary collaboration.The panel covers advancements in robotic systems, patient populations who benefit most from this approach, including those with high BMI, complex surgical histories, and fertility concerns, as well as the future of surgical innovation at Northwestern Medicine.This episode's panel of guests includes:• Emma L. Barber, MD, John and Ruth Brewer Professor of Gynecology and Cancer Research, Division Chief of Gynecologic Oncology and Director of Robotic Surgery.• Dario R. Roque, MD, Associate Professor of Gynecologic Oncology and Fellowship Program Director.• Jenna Z. Marcus, MD, Associate Professor of Gynecologic Oncology, Director of Robotic Simulation and Associate Fellowship Program Director.

Dr Dawn Mussallem survived Stage 4 Cancer and a full heart transplant when the odds of living were almost zero. In this episode, she reveals the mindset, lifestyle shifts, and healing practices that helped her not just survive — but thrive. If you are or one of your loved ones is facing cancer, fear, or any life-changing challenge, this conversation could completely shift your perspective.-MY BOOK IS NOW OUT AND AVAILABLE RIGHT NOW:⁠⁠⁠⁠https://axelschura.com/maybe/⁠⁠⁠⁠⁠⁠⁠⁠-DR DAWN MUSSALLEM:www.instagram.com/drdawnmussallem/ (Instagram)-BOOK YOUR CALL NOW:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://axelschura.com/the-evergreen-blueprint/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠-FREE LIVE WEBINAR FOR 10,000$ MONTHS AND DAYS:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://axelschura.com/live-webinar/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠-MY WEBSITE:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://axelschura.com/⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠-COACHING AND COMMUNITY:× 30 days FREE membership - change your life with my visualisation and meditation practices (new customers only):⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://axelschura.com/membership/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠× Free Webinar on Evergreen Products:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://event.webinarjam.com/register/6/yxqywig⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠× Free Strategy Session for Influencers, Agencies, Coaches, and Nutritionists:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://calendly.com/axelschurawlow/evergreen-blueprint⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠-SOCIALS:× Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://instagram.com/axelschura⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠× You can find me and my content on all social media platforms, just follow this Linktree: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/axelschura⁠⁠⁠⁠⁠⁠⁠⁠

Send us a text

 JR Richardson expressed overwhelming disbelief at his cancer-free diagnosis, stating he had been mentally prepared to die and was still recalibrating his mindset about surviving for his two children aged 15 and 17.Medical misdiagnoses occurred from 2018-2021 when JR's symptoms including pressure in his taint area were attributed to a fistula, fissure, and prostatitis rather than recognizing his PSA level of 21 as a cancer indicator.Healthcare providers failed to communicate the significance of JR's PSA level of 21, simply recommending a blood test without urgency, leading to a delayed diagnosis when his PSA reached 85.6 by the time of proper testing.Oncologist provided a grim prognosis of two to five years with palliative care options including abiraterone, steroids, and hormone blockers, offering no alternative treatment choices.JR declined conventional treatment initially, having been familiar with cannabis oil since Phoenix Tears and connected with Valerie Corral from WAMM, the first cannabis cooperative in the United States.Valerie Corral was identified as the pioneer who developed the 4:1 cannabis ratio and successfully sued the federal government after a farm raid, winning her case with Santa Cruz County support.Cannabis oil treatment began with JR taking a gram of oil he had made, but Corey Yelland advised switching to 4:1 ratio rectal administration for better effectiveness.PSA levels dropped dramatically from 85.6 to 29 within one month of starting 4:1 rectal cannabis treatment, and further decreased to 3.82 after receiving one hormone injection.Continued cannabis treatment brought PSA levels to normal range, with readings of 2.33, 1.82, and stabilizing around 1.72, demonstrating sustained improvement.Stanford Medical provided a second opinion contradicting the initial oncologist's palliative approach, recommending the Stampede Study protocol with pinpoint radiation on lymph nodes and two small spinal spots.Radiation treatment decision was made after consultation with a knowledgeable technician who explained advances in precision radiation technology, addressing JR's concerns about radiation damage based on his aunt's experience.Daily cannabis dosage consisted of at least one gram of CBG orally and two grams rectally with 10-20% lipid addition, plus additional oral THC, prioritizing survival over psychoactive effects.Valerie Corral's experience indicated that long-term cancer survivors in her practice had used both Western medicine and cannabis oil, influencing JR's decision to combine treatments.Recent scan results showed no metabolically active disease in previously affected areas including nodes and spine, confirming complete remission and validating the combined treatment approach. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What if cancer risk has far less to do with your weight than your insulin?Dr. Katie Deming sits down with Dr. Christy Kesslering, a fellow radiation oncologist who made the same unconventional leap out of Western medicine. Their conversation opens doors to understanding how metabolism influences cancer in ways most doctors never discuss with their patients.Dr. Kesslering reveals how her personal health struggles uncovered something most oncologists miss completely: insulin drives cancer growth far more than weight ever could. Chapters:05:32 - Emotional Roots of Cancer07:12 - Why She Left Radiation Oncology09:48 - Redefining Integrative vs Functional Medicine12:55 - The Power of Nutrient-Dense Real Food16:04 - The Most Revealing Cancer Biomarkers21:48 - Ketogenic Diet During Treatment26:35 - Steroids, Chemo, and Better Outcomes30:52 - Fasting vs Fasting Mimicking Diet36:22 - Radiation Protocols and Ketosis40:05 - Carnivore vs Carnivore-ish47:50 - Ketone Levels and Real-World HealingShe brings years of real clinical experience counseling patients on metabolic approaches right alongside their radiation treatment. You'll discover the specific blood markers that show what's truly happening beneath the surface and why your regular lab work probably isn't telling you the whole story.They break down exactly how to use fasting strategically around chemotherapy and radiation. Dr. Kesslering also tackles the truth about carnivore diets, hidden plant toxins, and why those trendy "fasting mimicking" packages might be doing more harm than good.You'll want to stay until the end because Dr. Kesslering reveals why chasing the "perfect" ketosis numbers might actually be sabotaging your healing, and what matters far more than any measurement you'll find in research studies.Listen and learn what two radiation oncologists discovered when they stopped treating symptoms and started addressing the metabolic terrain where cancer actually thrives.Connect with Dr. Christy Kesslering: Access the FREE Water Fasting Masterclass Now: https://www.katiedeming.com/the-healing-power-of-fasting/ Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieMORE FROM KATIE DEMING M.D. Work with Dr. Katie: www.katiedeming.com 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Email: INFO@KATIEDEMING.COM Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast Watch on Youtube: https://youtube.com/playlist?list=PL5LplU70TE9i01tW_7Tozi8b6X6rGBKA2&si=ZXLy5PjM7daD6AV5 DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.

On this episode, Dr. Debra A. Wong, Medical Oncologist at City of Hope and Medical Director at AccessHope, joins the podcast to discuss better supporting frontline oncologists in resource-limited settings, improving cancer care access, and the importance of not losing sight of the human element in care.

On this episode, Dr. Debra A. Wong, Medical Oncologist at City of Hope and Medical Director at AccessHope, joins the podcast to discuss better supporting frontline oncologists in resource-limited settings, improving cancer care access, and the importance of not losing sight of the human element in care.

On this episode, Dr. Debra A. Wong, Medical Oncologist at City of Hope and Medical Director at AccessHope, joins the podcast to discuss better supporting frontline oncologists in resource-limited settings, improving cancer care access, and the importance of not losing sight of the human element in care.

Lauren, a native of Madison, WI, graduated with a B.S. in Molecular Biology and Spanish from the University of Wisconsin–Madison. She then earned her M.D. at Stanford University, where she was awarded a Howard Hughes Medical Institute (HHMI) research scholarship to study osteosarcoma at the National Cancer Institute (NCI) in Washington, D.C. She completed her internship at Santa Clara Valley Medical Center in San Jose, CA, followed by a residency in radiation oncology at Memorial Sloan-Kettering Cancer Center in New York City. After residency, Lauren joined the faculty of the University of Wisconsin Carbone Cancer Center, where she focused on thoracic radiation oncology and helped develop a spine stereotactic radiation program. In 2014, she transitioned to The Permanente Medical Group, serving as a radiation oncologist at Kaiser Permanente in Northern California and later as regional lymphoma subspecialty lead until her departure in 2023. She then joined the University of Colorado Department of Radiation Oncology, where she served on the faculty until June 2025.Lauren is currently pursuing additional training in palliative care while continuing to provide locum tenens radiation oncology coverage across Colorado and California. She is passionate about delivering evidence-based, patient-centered care—a commitment that is deeply personal and influenced by her experiences watching both of her parents undergo cancer treatment.The desire to be closer to friends and family—and a shared love of the outdoors—brought Lauren and her family to Colorado. She resides in Morrison with her husband, Anthony, a native of England who runs a consulting practice specializing in cell and gene therapies. Together they enjoy the lively company of their two children, Anna and Charlie, along with an ever-growing menagerie of pets. As a family, they love hiking, gardening, sharing tea and biscuits, and catching up on sleep whenever possible.**********************************************************Judy Carlson is the CEO and Founder of the Judy Carlson Financial Group, where she helps couples create personalized, coordinated financial plans that support the life they want to live – now and in the future.As an Independent Fiduciary and Comprehensive Financial Planner, Judy specializes in retirement income and wealth decumulation strategies. She is a CPA, Investment Advisor Representative, licensed in life and health insurance, and certified in long-term care planning.Judy's mission is to help guide clients with clarity and care, building financial plans that focus on real planning built around real lives.Learn More: https://judycarlson.com/The Inspired Impact Podcasthttps://businessinnovatorsradio.com/the-inspired-impact-podcast/Source: https://businessinnovatorsradio.com/the-inspired-impact-podcast-with-judy-carlson-interview-with-lauren-shapiro-md-radiation-oncologist

How might the advent of IDH inhibitors impact the practice of radiation oncologists and their role within the wider multidisciplinary team? Credit available for this activity expires: 11/20/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/highlights-san-francisco-evolving-role-radiation-oncologist-2025a1000uyk?ecd=bdc_podcast_libsyn_mscpedu

Send us a text

GDP Script/ Top Stories for November 20th Publish Date: November 20th PRE-ROLL: SUGAR HILL ICE SKATING From the BG AD Group Studio Welcome to the Gwinnett Daily Post Podcast. Today is Thursday, November 20th and Happy birthday to Bobby Kennedy I’m Peyton Spurlock and here are your top stories presented by KIA Mall of Georgia. Lawmakers consider paring tax credits and exemptions to offset income tax cuts Piedmont Eastside and Piedmont Oncology welcome medical oncologist Sami Ali Gwinnett commissioners to issue bonds for Gas South Arena renovations Plus, Leah McGrath from Ingles Markets on rice All of this and more is coming up on the Gwinnett Daily Post podcast, and if you are looking for community news, we encourage you to listen daily and subscribe! Break 1: STRAND THEATRE STORY 1: Lawmakers consider paring tax credits and exemptions to offset income tax cuts  Georgia lawmakers are seriously considering wiping out the state income tax—$16 billion in revenue—and replacing it by slashing $30 billion in tax credits and exemptions. “It’s not if, it’s when,” said Sen. Blake Tillery, who’s leading the charge. He called it a move for “competitiveness.” Supporters like economist Arthur Laffer praised states like Tennessee for thriving without income taxes, calling it “really cool” not to file returns. But critics, like Sen. Nan Orrock, warned it could hit low-income families and retirees hardest, especially if sales taxes rise. The debate? Far from settled. STORY 2: Piedmont Eastside and Piedmont Oncology welcome medical oncologist Sami Ali  Piedmont Eastside Medical Center and Piedmont Oncology are thrilled to welcome Dr. Sami Ali to their team. Dr. Ali, a board-certified hematologist and oncologist, brings years of experience treating patients with lung cancer, colorectal cancer, blood disorders, and more. Before joining Piedmont, Dr. Ali spent eight years at The Oncology Institute in Los Angeles, where he provided personalized care, led treatment plans, and contributed to clinical research. “We’re excited to have him,” said Larry Ebert, Piedmont Eastside’s CEO. “His expertise will help us expand cancer care in Gwinnett County.” Dr. Ali is now accepting new patients. For appointments, visit Piedmont.org or call 678-639-3950. STORY 3: Gwinnett commissioners to issue bonds for Gas South Arena renovations   Gwinnett County commissioners took a big step Tuesday toward funding a major facelift for the 23-year-old Gas South Arena. The plan? Revenue bonds—up to $172 million worth—to cover renovations like new seating, upgraded security, better concessions, and even a shiny new parking deck. The total cost? Somewhere between $170 and $176 million. The county might chip in $40 million to ease the debt load, according to Financial Services Director Russell Royal. What’s changing? Think premium seating, revamped suites, modernized restrooms, grab-and-go food, and a high-tech security plaza. Oh, and the roof, HVAC, and electrical systems? All getting replaced. We have opportunities for sponsors to get great engagement on these shows. Call 770.874.3200 for more info. We’ll be right back Break 2: 07.14.22 KIA MOG STORY 4: Georgia Gwinnett College celebrates International Education Week   Georgia Gwinnett College turned International Education Week into a colorful, culture-packed celebration that brought the world to campus. From Nov. 10, students and staff dove into 14 events—everything from global traditions to study-abroad opportunities. The highlight? A visit from Lithuania’s Consul General, DOH-vee-dahs Dovydas shpo-KOW-skas Špokauskas, who spoke on diplomacy and security, thanks to professor DOH-vee-leh Dovilė boo-DREE-teh Budryte. Korean culture stole the show at Seoul Connections, with K-Pop, snacks, and games filling the room. And the International Thanksgiving? A feast of global flavors, live music, and a cultural fashion show. The week wrapped with poetry, music, and a reminder: the world’s waiting—go explore it. STORY 5: Gwinnett waiving tax penalties for residents impacted by government shutdown Gwinnett County is throwing a lifeline to residents hit hard by the recent federal shutdown. On Tuesday, commissioners gave Tax Commissioner Denise Mitchell the green light to waive penalties and interest on late ad valorem taxes for those furloughed or who lost SNAP benefits during the chaos. “Georgia law lets me waive penalties for reasonable cause,” Mitchell explained. “And over the past few weeks, I’ve heard from residents struggling to pay their bills because of the shutdown.” This doesn’t erase the taxes—just the late fees. To qualify, folks need proof of furlough or lost benefits, and the waiver only covers bills due during or shortly after the shutdown. We’ll be right back. Break 3: THE SUGAR HILL HOLIDAY And now here is Leah McGrath from Ingles Markets on rice Break 4: BUFORD HOLIDAY FESTIVAL We’ll have closing comments after this Break 5: Ingles Markets 8 Signoff – Thanks again for hanging out with us on today’s Gwinnett Daily Post Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at www.gwinnettdailypost.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: www.ingles-markets.com www.kiamallofga.com Strand Marietta – Earl and Rachel Smith Strand Theatre Ice Rink – Downtown Sugar Hill Holiday Celebration 2025 – City of Sugar Hill 2025 Buford Holiday Festival & Parade All-In-One Flyer News Podcast, Current Events, Top Headlines, Breaking News, Podcast News, Trending, Local News, Daily, News, Podcast, Interviews See omnystudio.com/listener for privacy information.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/ZSR865. CME/AAPA credit will be available until October 29, 2026.To Glycemia and Beyond: Managing Cardiovascular Risk in People With Type 2 Diabetes Using Incretin-Based Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Melissa sits down with Dr. Laila Agrawal, a board-certified breast oncologist who leads a sexual health clinic dedicated to the breast cancer community. As part of the "Empowered Intimacy: Getting Your Sexy Back After Breast Cancer" series, they talk about how to restore sexual comfort, pleasure, and connection after a breast cancer diagnosis. Dr. Agrawal offers practical guidance on vibrators, lubricants, vaginal estrogen, and pelvic floor therapy, while clearing up common misconceptions and stressing the importance of open communication with both partners and providers. This episode focuses on both the emotional and physical sides of intimacy and teaches listeners how to regain desire, comfort, and confidence in their sexual health after a breast cancer diagnosis. Special thanks to Lilly and Novartis for supporting the Cancer Fashionista Foundation and making this series possible.

In this episode, Joe Moore sits down with Dr. Jason Konner, a longtime oncologist who recently left his full-time clinical role at Memorial Sloan Kettering to devote himself to the emerging intersection of cancer care and psychedelics. Dr Konner shares how, after more than two decades treating people, he hit a wall. The accumulated grief, constant exposure to death, and intensity of oncology left him deeply burned out, though he didn't have that language for it at the time. A chance moment in a yoga class, overhearing someone say "ayahuasca retreat" just before he was scheduled for hernia surgery, became the turning point. Within a week, he was in the jungle. That first week with ayahuasca, followed later by work with mushrooms, "absolutely transformed" his life. His fear of death lifted. The burnout he hadn't even recognized in himself was both revealed and relieved. When he returned to his practice, Konner describes feeling like he suddenly had a "superpower": he could stay present, connected, and compassionate with patients facing advanced disease without collapsing under the emotional weight. He and Joe explore what this third path looks like: not the classic binary between either hardening and distancing as self-protection, or staying open-hearted and getting shattered. Instead, psychedelics helped him hold deep relationship with patients and families while maintaining inner stability and meaning. This opened space for authentic conversations about spirituality, fear, grief, and what it means to live with (or die from) cancer. From there, Dr Konner zooms out to critique the broader oncology system: The lack of training and support for oncologists around their own emotional and existential load, How little space there is for relational work even though it's central to healing, Why many support groups and standard psychiatric approaches (like reflexively prescribing SSRIs) often miss the mark for people dealing with cancer, How caregivers, partners, family members, and others are deeply affected but rarely truly supported. Joe and Jason then dig into psychedelics and oncology as a frontier: easing existential distress in patients with terminal cancer, the neglected suffering of caregivers, the potential role of psychedelics in helping people relate differently to death, and what it might mean for ICU use, aggressive end-of-life interventions, and overall healthcare costs if more people could make decisions from a place of peace rather than terror. Dr Konner also shares a striking ovarian cancer case that hinted at powerful immune changes after shamanic work, and why he believes we need new research paradigms that can honor the integrity of retreat and ceremonial settings while still learning from them. Finally, he talks about his early-stage project, Psychedelic Oncology, and his hope that the first wave of change starts with clinicians themselves becoming more psychedelic-literate—and, where appropriate, doing their own inner work—so better options can eventually reach the people who need them most. Learn more - https://psychedeliconcology.com/

I feel honoured to share this third conversation with Jannine Gearon who I interviewed before in May and June this year. Jannine lives with cholangiocarcinoma (bile duct cancer) - a rare and aggressive cancer with very confronting statistics. In our previous two episodes, she bravely shared her journey, including her decision to explore voluntary assisted dying (VAD) as a way of reclaiming a sense of choice amidst pain and uncertainty. Today, there's a plot twist. A newly available targeted drug, found by her sister at what felt like the literal 11th hour, has begun changing the trajectory of her disease. Her latest scan and bloods show things are not progressing as expected - in the best possible way. As Jannine says, “the cancer is not behaving as it should,” and her oncologist is now cautiously optimistic. May this episode entangle in the quantum field with the exact people who are meant to hear it, and create beautiful ripples in your life and the lives of those you love.

Send us a text

Featuring an interview with Dr Aaron Lisberg, including the following topics: Prevention and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (Dato-DXd) (0:00) Rugo H et al. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Support Care Cancer 2025;33(9):756. Abstract Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;[Online ahead of print]. Abstract Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 2025;30(3). Abstract Novel Strategies Combining Dato-DXd with Osimertinib (10:44) Lu S et al. TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC). ASCO 2025;Abstract TPS8647. Nadal E et al. TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib. ELCC 2025;Abstract 124TiP. Intracranial Activity Observed with TROP2-Targeting Antibody-Drug Conjugates (15:14) Felip E et al. Brain metastases and actionable genetic alterations with sacituzumab govitecan versus docetaxel in metastatic non-small cell lung cancer: Subgroups of the phase III EVOKE-01 trial. ELCC 2025;Abstract 13P. Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593. Pons-Tostivint E et al. Intracranial efficacy of datopotamab deruxtecan (Dato- DXd) in patients with advanced/metastatic NSCLC in TROPION-Lung01. WCLC 2025;Abstract OA10.01. CME information and select publications

Dr. Adir Ludin shares his own story and the story of radiation oncology. In the telling, his humanity and technical expertise shine through.

Send us a text

Featuring an interview with Dr Kevin Kalinsky, including the following topics: Prophylaxis, Monitoring and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (0:00) Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;30(9). Abstract  Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 2025;30(3). Abstract   Clinical Data with Neoadjuvant Datopotamab Deruxtecan from the I-SPY 2.2 Phase II Trial (5:17) Khoury K et al. Datopotamab–deruxtecan in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med 2024;30(12):3728-36. Abstract  Shatsky RA et al. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 Phase II trial. Nat Med 2024;30(12):3737-47. Abstract  NeoSTAR: A Phase II Study of Response-Guided Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Localized Triple-Negative Breast Cancer (9:09) Abelman RO et al. A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. ASCO 2025;Abstract 511.  OptimICE-RD: A Phase III Study Evaluating Sacituzumab Govitecan with Pembrolizumab versus Pembrolizumab with or without Capecitabine for Residual Triple-Negative Breast Cancer (12:56) Tolaney SM et al. OptimICE-RD: Sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer. Future Oncol 2024;20(31):2343-55. Abstract  CME information and select publications

Dr. Robert Kimutai is a Paediatric Hematologist–Oncologist who joined MP Shah in July 2025. He diagnoses and treats children with blood disorders and cancer. He also attends to general paediatric patients in the hospital. His interests are in advancing care of blood disorders, cancer in children through a multidisciplinary approach and establishing a bone marrow transplant service in Kenya

In this episode of, "Empowered Intimacy: Getting Your Sexy Back After Breast Cancer," we open up an important conversation about sexual health after a breast cancer diagnosis. Melissa is joined by her friend Deltra, a mom of five living with triple-negative metastatic breast cancer, and Dr. Laila Agrawal, a board-certified medical oncologist dedicated to putting sexual health at the forefront of cancer care. Many carry these concerns silently, but intimacy is an important part of quality-of-life care. Together, they share personal stories, explore why this topic is often overlooked, and offer practical tips for starting the conversation with your doctor, asking the right questions, and advocating for the support and resources that you deserve. Special thanks to Lilly, Merck, and Novartis for supporting the Cancer Fashionista Foundation and making this episode possible.

Dr. Meredith Whittaker says early detection is the key to saving lives and achieving the best possible outcomes in breast cancer treatment. She discusses the emotional and physical challenges patients face during breast surgery and how doctors work to support them every step of the way. Dr. Whittaker also spotlights cutting-edge advancements in surgical techniques and technology that are transforming care and improving recovery times. For information visit breastcare.mwhc.com.

They started off by introducing themselves as The Three Horsemen of the Apocalypse - what could possibly go wrong!! Declan couldn't resist the opportunity to invite three very eminent radiation oncologists into the studio when they all happened to be in Melbourne, even if he was particularly outnumbered while Renu was away! Vedang Murthy (Tata Memorial, India), Andrew Loblaw (Sunnybrook Hospital, Canada), and Sarat Chander (Peter Mac, Melbourne) are all highly specialised in prostate radiation, so Declan invited them into the GU Cast studio to pick their brains on three big areas in prostate radiation:1. Hypofractionation in 2025 - Who and How?2. Who needs ADT and for how long when having prostate radiation?3. Metastasis-directed therapy for oligometastatic disease - is there any point??Tune in to find out how Urologist Declan Murphy fared up against these three Radiation Oncologists!!! Even better on our YouTube channelThis podcast is supported by our Bronze Partner, Icon Cancer Centre.

In this powerful Breast Cancer Awareness Month rerun episode, we're joined once again by renowned breast cancer oncologist Dr. Amy Comander to explore the vital connection between lifestyle medicine and breast cancer prevention, treatment, and survivorship.Dr. Comander shares expert insights on how nutrition, exercise, stress management, and other evidence-based lifestyle changes can significantly reduce your risk of breast cancer, support recovery, and enhance long-term health outcomes.Whether you're a patient, survivor, caregiver, or simply looking to take proactive steps toward better health, this episode offers practical, science-backed strategies for early detection, cancer prevention, and overall wellness. Tune in now to empower yourself with life-changing knowledge and actionable steps from one of the field's leading voices.

In this deeply moving episode, I sit down with Dr. Carol Haddad, integrative oncologist and founder of Integrative Cancer Care Australia (ICCA), to explore a powerful truth: the patient is the creator of their own medicine. We talk about cancer as a catalyst, the evolving role of integrative care, and the importance of love as the medicine - not romantic love, but the consciousness of love that transforms the healing journey. Together, we reflect on the paradox of will and surrender, the unseen power of bedside manner as energetic transmission, and a beautiful new concept: remission of the mind where the mind learns to live in harmony with a healed body. This conversation is for those navigating cancer, their loved ones, and the medical professionals ready to hear a new paradigm in healing. May it ripple out as medicine you didn't know you were seeking. Work with Dr Carol Haddad Dr Carol Haddad https://www.drcarolhaddad.com/ ICCA https://www.integrativecancercare.com.au/ Retreat (Byron Hinterland, 28 October - 2 November 2025) https://ripplehealing.com.au/multidimensional-healing-reatreat/ Dr Carol Haddad drcarolhaddad@gmail.com & ICCA  info@icca.com.au   Work with me https://www.giselegambi.com.au/ 1:1 Immersion: deep, bespoke transmutation work https://www.giselegambi.com.au/liberated Group container: The Presence Room https://www.giselegambi.com.au/the-presence-room Please feel free to connect with me via DM or gisele@giselegambi.com.au Facebook https://www.facebook.com/gisele.gambi/ Instagram https://www.instagram.com/authenticgisele/   YouTube I'm pouring love into YouTube: long-form episodes, Shorts, meditations, and series - all organised like a living library. Subscribe: https://www.youtube.com/@giselegambi1   00:00 Welcome & intention: “Let this be the medicine people didn't know they were looking for” 00:27 Reunion with Dr. Carol Haddad - past conversations & why this one matters 01:14 Who is Dr. Carol Haddad? From hospital oncology to integrative care 02:40 The spectrum: conventional → alternative → the “middle way” 03:19 Why the same cancer protocol works for some and not others 04:00 Love as medicine & higher-level thinking 05:13 The patient is the creator of their medicine 06:54 Self-advocacy, radical remission, and patient-led healing 08:14 Shifting from powerlessness to partnership in cancer care 08:49 Cancer as catalyst: love, surrender & coming home to self 09:29 Control, self-denial, and how cancer can undo old patterns 10:30 What Carol would say to someone with cancer ready to hear this message 11:24 Suppression & self-denial as risk factors; cancer as awakening 12:21 Wholeness after cancer & receiving the blessing in unexpected ways 12:38 Healing in our hands - and beyond them (non-attachment) 13:38 The paradox: fire & will vs. surrender and letting go 14:58 Message to the medical profession: conscious consultation 15:41 Bedside manner as energetic transmission; practitioner self-work 18:40 Language, prognosis & evoking patient power 20:12 How careless words can create fear - and how to restore power 21:21 A personal story: cardiologists, energy, and love as medicine 21:36 Humbling moments: loss, learning, and what's still missing 22:51 Radical remissions & what patients teach us 23:34 Ripple effects: healing leading to businesses, books & community impact 25:10 A new concept: remission of the mind 27:10 Retreat invitation: multidimensional healing (Byron, 28 Oct - 2 Nov 2025) 29:34 Coming ICCA e-course & evolving access to integrative cancer care 30:33 Closing blessing: may this be the medicine you were seeking   #CancerHealing #IntegrativeOncology #LoveIsTheMedicine #ICCA #CancerCare #RadicalRemission #HealingJourney #IntegrativeMedicine #RemissionOfTheMind #PatientEmpowerment #ConsciousConsultation #Oncology #CancerSupport #HolisticHealing

In this enlightening conversation, Jen Delvaux sits down with Anna Crollman to explore the often-overlooked aspects of cancer survivorship. Together, they uncover the emotional, physical, and relational challenges survivors face long after treatment ends. Anna shares her personal journey with breast cancer, how she's navigating bone health, and why she embraced GLP-1 therapy as part of her healing. This heartfelt discussion emphasizes the power of self-advocacy, the importance of holistic care, and the role of community in thriving beyond a diagnosis.

Every year, millions of people's medical care runs into the roadblock known as prior authorization, which requires an insurer to sign off before chemotherapy, surgery or countless other services can proceed. Who does this often onerous process help, who does it hurt and how could it work better for everyone?Guests:Tom Roberts, Oncologist, Mass General Cancer CenterAaron Schwartz, Assistant Professor, Department of Medical Ethics and Health Policy and Department of Medicine, University of PennsylvaniaKathleen, CaregiverLearn more on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

In this episode of The Buzz, LM Bennett discusses her transition from bench science to team science at the NIH and NCI, co-authoring a field guide, and her new book, 'How to Succeed at Collaborative Research: A Practical Guide for Teams.' The conversation delves into the significance of trust, emotional intelligence, and effective communication in scientific collaborations, as well as the challenges of virtual teamwork. She also shares insights on designing successful retreats and fostering interdisciplinary teams, emphasizing the importance of intentionality and preemptive planning in collaborative efforts.HOME | LM Bennett Consulting Subscribe on your favorite podcast platform to never miss an episode! For more from ACT-IAC, follow us on LinkedIn or visit http://www.actiac.org.Learn more about membership at https://www.actiac.org/join.Donate to ACT-IAC at https://actiac.org/donate. Intro/Outro Music: See a Brighter Day/Gloria TellsCourtesy of Epidemic Sound(Episodes 1-159: Intro/Outro Music: Focal Point/Young CommunityCourtesy of Epidemic Sound)

In this episode, Dr. Russell Berman sits down with Dr. Sandra Wong, Dean of Emory University School of Medicine, and Dr. David Linehan, Dean of University of Rochester School of Medicine and Dentistry. Together, they share what it means to step beyond the operating room and into the role of shaping the future of medical education.  From leading surgical oncology programs to leading entire medical schools, Drs. Wong and Linehan discuss their journeys, the challenges of balancing clinical, research, and administrative responsibilities, and how surgical oncologists are uniquely positioned to guide the next generation of physicians.

The Future of Cancer Care: The Next Generation of Oncologists with guests Drs. Etienne Leveille and Nicole Casansanta September 14, 2025.

LOGAN HEALTH PEDIATRIC HEMATOLOGIST ONCOLOGIST RACHEL DR. RACHEL BRENNAN TRT: 16:40

Doctors often use euphemisms to dance around the 'C' word. But for oncologist Dr Ranjana Srivastava, how you talk to someone with cancer goes beyond "shadows, lumps and lesions". It's all about compassion and clarity, even when honesty is difficult.Ranjana Srivastava was a young doctor in regional Australia, accompanying her consultant on his late night rounds when she heard a patient say something that stopped Ranjana in her tracks.It was in that moment that she finally knew what her speciality was going to be: oncology. Ranjana now works in Melbourne as an oncologist and an author.She often writes about the need for clarity and compassion in doctor-patient conversations, to deliver good news, bad news and everything that falls between.Ranjana had her own experience of being at the receiving end of devastating news when she was pregnant with twins.Ranjana has carried the lesson she received from her own doctor forward, into her work as an oncologist, where bearing witness to the attitudes of her patients has changed the way she sees the world and has helped put her own life in perspective.Further informationRanjana's latest book, Every Word Matters, is published by Simon & Schuster.She has published seven books about cancer and end of life care, including A Better Death, Tell Me the Truth, Dying for a Chat, So It's Cancer: Now What, and After Cancer: A Guide to Living Well.Ranjana also writes a regular column for The Guardian.In 2017, Ranjana was awarded an Order of Australia medal for her work as an oncologist and in improving doctor-patient communication.This episode of Conversations was produced by Meggie Morris. Executive producer is Nicola Harrison.It explores cancer, oncology, the big C, cancerland, breast cancer, bowel cancer, how to survive cancer, incurable cancer, end of life care, palliative care, honest doctors, refusing treatment, chemotherapy, radiation, how to be honest with patients, doctor patient relationship, geriatric oncology, India, migration, motherhood, late term miscarriage, pregnancy, writing, books, origin story, journalism.To binge even more great episodes of the Conversations podcast with Richard Fidler and Sarah Kanowski go the ABC listen app (Australia) or wherever you get your podcasts. There you'll find hundreds of the best thought-provoking interviews with authors, writers, artists, politicians, psychologists, musicians, and celebrities.

Enhancing Post-Cancer Care: Integrative Approaches with Dr. Megan BernardWhat happens after cancer treatment ends? Too often, survivors are left without a clear roadmap for long-term healing and prevention. In this episode of the Believe Big Podcast, Ivelisse  sits down with Dr. Megan Bernard, a board-certified naturopathic doctor passionate about guiding patients through comprehensive cancer recovery.Together, they talk about how mindset can shape healing, why many critical tests are often overlooked in conventional care, and the importance of personalized monitoring after treatment. Dr. Bernard shares the latest insights on functional and integrative approaches—including epigenetic testing, immune and metabolic profiling, and innovative therapies like mistletoe—that are helping patients thrive beyond survival.Listeners will walk away with:Practical questions to ask your oncologist about integrative therapiesStrategies for combining conventional and complementary care for the best outcomesHope-filled insights into the future of personalized cancer recoveryWhether you're a survivor, caregiver, or simply curious about holistic approaches to health, this episode offers empowering tools and encouragement for the journey ahead.Learn More About Dr. Megan Bernard:Flourish, The Roadmap to RecoverySuggested Resources:Dr. Megan Bernard's Instagram Dr. Megan's PodcastDr. Megan's BlogDUTCH Test - Dried Urine Test for Comprehensive HormonesSignatera Test - personalized cancer testingSummary of Helixor StudiesHelixor - Breast Cancer literatureSend us Fan Mail! Click here >Your donations power our podcast's mission to support cancer patients with hope, insights, and resources. Every contribution fuels our ability to uplift and empower. Join us in making a lasting impact. Donate now!

Small cell lung cancer was once considered one of the most challenging diagnoses in oncology. But today, groundbreaking treatments are transforming patient outcomes and rewriting survival stories. Discover how immunotherapy, T-cell engagers, CAR T-cell therapy, and antibody drug conjugates are moving from clinical trials to standard care, offering patients years of disease control and genuine hope for the future. Featuring insights from Dr. Jacob Sands, thoracic oncologist at Dana-Farber Cancer Institute, and inspiring patient advocate Wendy Brooks, who shares her powerful journey from early detection through cutting-edge clinical trials, proving that advocacy and hope can change everything. Guests: Dr. Jacob Sands, Oncologist, Dana-Farber Cancer Institute Courtney Mantz, Program Manager II, SCLC Program, Dr. Sands' Assistant. Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology Wendy Brooks, Patient Advocate Show Notes | Transcript | Watch Video

What really causes cancer? Will we ever find a cure? And why does our mistrust of medicine and obsession with big pharma conspiracies have such a grip on the way we think about it? In this episode, Jonathan Van Ness sits down with oncologist Dr. Stacy Wentworth to explore the biggest questions surrounding cancer—what science can tell us, what it can't (yet), and how to reframe the way we talk about this disease. From cutting through fear and misinformation to finding space for hope and empowerment, this conversation offers clarity and compassion for anyone touched by cancer. Full Getting Better Video Episodes now available on YouTube.  Follow Dr. Stacy Wentworth on Instagram @drstacywentworth  Follow us on Instagram @gettingbetterwithjvn  Follow Jonathan on Instagram @jvn Follow Dr. Stacy's Substack here.  BIO: Dr. Wentworth is an award-winning physician, author, and cancer survivorship expert.  She has two decades of experience leading patient centered care teams in diverse settings – from NCI designated comprehensive cancer centers to rural hospitals. Her research has been featured at national conferences and published in peer-reviewed journals. Dr. Wentworth is the founder of the Cancer Culture Substack, where she explores how personal beliefs, history, and science influence our experience and attitude toward cancer. Senior Producer, Chris McClure Producer, Editor & Engineer is Nathanael McClure Production support from Anne Currie and Chad Hall Our theme music is also composed by Nathanael McClure. Check out the JVN Patreon for exclusive BTS content, extra interviews, and much much more - check it out here: www.patreon.com/jvn Curious about bringing your brand to life on the show? Email podcastadsales@sonymusic.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Misinformation can spread quickly, especially when it comes to health care. Lately, some cancer patients have been asking about the use of Ivermectin, a drug designed to treat parasites, as a potential cancer treatment. Bayan Al-Share, M.D., Oncologist at Monument Health Cancer Care Institute, joins host Mark Houston to address where this idea came from, what the science actually says and how to evaluate sources of medical information. Dr. Al-Share also shares how she handles these conversations in the exam room and what patients should know before considering alternative therapies. Hosted on Acast. See acast.com/privacy for more information.

To the medical teams walking alongside us, this is what every caregiver wishes you knew.In the final episode of the "Things I Wish You Would Know" series, Charlotte speaks directly to oncologists, nurses, and care providers.This is not about blame, it's about partnership. It's about being seen as more than "just the caregiver," and recognizing how much caregivers carry when the appointments end.If you've ever wanted your voice heard in those clinical rooms, this episode says what so many cancer caregivers feel but can't always say.Find your free Scanxiety Toolkit at https://www.cancercaregiverpodcast.com/tools

The Cancer Therapies You're Not Being Told About This episode goes straight into the treatments that rarely make it past the walls of a conventional oncology clinic. I'm talking red light therapy, chlorine dioxide solution (CDS), and even urine therapy, modalities backed by real science, used around the world, and showing results in cancer recovery, thyroid health, autoimmune conditions, wound healing, autism, chronic fatigue, and more. I'm joined by Jonathan Otto, researcher, educator, and producer of groundbreaking health documentaries who pulls back the curtain on what's working for patients right now. He shares case studies you won't hear in a standard medical appointment, breaks down the research hiding in plain sight, and explains exactly how these approaches fit into real-world healing protocols. We're also taking on the myths, the misinformation, and the reasons therapies with Nobel Prize-level science behind them are still being ignored. This is a candid, fact-driven conversation designed to help you see your options clearly, so you can make informed decisions about your health without limits placed on you by outdated systems. If you've been told there's only one path forward, this episode will give you a much wider view. Connect with Jonathan Otto: Instagram: @jonno.otto

Endocrine disruptors are chemicals that can interfere with the complex system that produces and interacts with our hormones. Research suggests they can affect the reproductive system, our kidneys, and even increase our risk of cancer. There are over 1,000 types of endocrine-disrupting chemicals, according to some estimates, and we are exposed to them daily through things like kitchen utensils and makeup. So how worried should we be about inevitable exposure?Host Elahe Izadi speaks with oncologist Dr. Mikkael Sekeres about the connection between endocrine disruptors and cancer. Dr. Sekeres also shares his advice on steps he takes to avoid these chemicals–and how he puts the risks into perspective.Today's show was produced by Thomas Lu, with help from Rennie Svirnovskiy, who also mixed the episode. It was edited by Ariel Plotnick. Subscribe to The Washington Post here.

Save your spot for the next LIVE fasting call here: https://www.katiedeming.com/the-healing-power-of-fasting/What if everything you've been told about preventing cancer is actually making you sicker?Dr. Katie Deming guests on Chris and Kevin Carton's Science and Spirituality Podcast to share her radical shift from respected radiation oncologist to pioneer of Conscious Oncology. Dr. Deming is helping people achieve what many doctors believe is impossible: true healing from cancer, in some cases without chemo or radiation. Drawing from her integrative approach, she unpacks why cancer rates are still rising despite trillions spent on research, and why modern life tap water, seed oils, blue light, processed food, and emotional trauma may be silently undermining our health.Key Takeways:Why your filtered water may still be toxic and how to fix itThe fourth phase of water most doctors never learn aboutWhy morning sunlight, not sunscreen, may be the missing nutrient in your routineHow unprocessed trauma and emotional patterns contribute to illnessThe mindset shift that helped two of her clients achieve full remission in just five months.They're not talking about perfection or expensive protocols, but remind us how we were designed to live and heal.Listen and learn specific, accessible tools starting with something as simple as adding the right salt to your water or getting barefoot on the earth. Science and Spirituality Podcast: https://pod.link/1474893910Save your spot for the next LIVE fasting call here: https://www.katiedeming.com/the-healing-power-of-fasting/ Reserve Your Spot for the August PSYCH-K® Online Workshop - Level 1: https://l.bttr.to/8Emui Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieMORE FROM KATIE DEMING M.D. Save your spot for the next LIVE fasting call here: https://www.katiedeming.com/the-healing-power-of-fasting/ Work with Dr. Katie: www.katiedeming.comEmail: INFO@KATIEDEMING.COM 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.

The incidence of early onset colorectal cancer (EOCRC) has been rising prompting the change in change in screening guidelines to 45 years of age for average risk patients. Join us for an in-depth discussion with guest speakers Dr. Andrea Cercek and Dr. Nancy You, where we provide a comprehensive look at the growing challenge of EOCRC. Hosts: - Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center - Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian - Dr. Phil Bauer, Graduating Colorectal Surgical Oncology Fellow at Memorial Sloan Kettering Cancer Center  - Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer Center - Dr. Andrea Cercek - Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center - Dr. Y. Nancy You, MD MHSc - Professor, Department of Colon and Rectal Surgery at MD Anderson Cancer Center Learning objectives:  - Describe trends in incidence of colorectal cancer, with emphasis on the rise of EOCRC. - Identify age groups and demographics most affected by EOCRC. - Summarize USPSTF recommendations for colorectal cancer screening. - Distinguish between screening methods (e.g., colonoscopy, FIT-DNA) and their sensitivity. - Understand treatment approaches for colon and rectal cancer (CRC) - Understand the role of mismatch repair (MMR) status in guiding treatment. - Outline the importance of genetic counseling and testing in young patients. - Discuss racial, ethnic, and socioeconomic disparities in CRC incidence and outcomes. - Describe the impact of cancer treatment on fertility and sexual health. -  Review fertility preservation options. - Identify the value of integrated care teams for young CRC patients. References: 1.         Siegel, R. L. et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. JNCI J. Natl. Cancer Inst. 109, djw322 (2017). https://pubmed.ncbi.nlm.nih.gov/28376186/ 2.         Abboud, Y. et al. Rising Incidence and Mortality of Early-Onset Colorectal Cancer in Young Cohorts Associated with Delayed Diagnosis. Cancers 17, 1500 (2025). https://pubmed.ncbi.nlm.nih.gov/40361427/ 3.         Phang, R. et al. Is the Incidence of Early-Onset Adenocarcinomas in Aotearoa New Zealand Increasing? Asia Pac. J. Clin. Oncol.https://pubmed.ncbi.nlm.nih.gov/40384533/ 4.         Vitaloni, M. et al. Clinical challenges and patient experiences in early-onset colorectal cancer: insights from seven European countries. BMC Gastroenterol. 25, 378 (2025). https://pubmed.ncbi.nlm.nih.gov/40375142/ 5.         Siegel, R. L. et al. Global patterns and trends in colorectal cancer incidence in young adults. (2019) doi:10.1136/gutjnl-2019-319511. https://pubmed.ncbi.nlm.nih.gov/31488504/ 6.         Cercek, A. et al. A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. J. Natl. Cancer Inst. 113, 1683–1692 (2021). https://pubmed.ncbi.nlm.nih.gov/34405229/ 7.         Zheng, X. et al. Comprehensive Assessment of Diet Quality and Risk of Precursors of Early-Onset Colorectal Cancer. JNCI J. Natl. Cancer Inst. 113, 543–552 (2021). https://pubmed.ncbi.nlm.nih.gov/33136160/ 8.         Standl, E. & Schnell, O. Increased Risk of Cancer—An Integral Component of the Cardio–Renal–Metabolic Disease Cluster and Its Management. Cells 14, 564 (2025). https://pubmed.ncbi.nlm.nih.gov/40277890/ 9.         Muller, C., Ihionkhan, E., Stoffel, E. M. & Kupfer, S. S. Disparities in Early-Onset Colorectal Cancer. Cells 10, 1018 (2021). https://pubmed.ncbi.nlm.nih.gov/33925893/ 10.       US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 325, 1965–1977 (2021). https://pubmed.ncbi.nlm.nih.gov/34003218/ 11.       Fwelo, P. et al. Differential Colorectal Cancer Mortality Across Racial and Ethnic Groups: Impact of Socioeconomic Status, Clinicopathology, and Treatment-Related Factors. Cancer Med. 14, e70612 (2025). https://pubmed.ncbi.nlm.nih.gov/40040375/ 12.       Lansdorp-Vogelaar, I. et al. Contribution of Screening and Survival Differences to Racial Disparities in Colorectal Cancer Rates. Cancer Epidemiol. Biomarkers Prev. 21, 728–736 (2012). https://pubmed.ncbi.nlm.nih.gov/22514249/ 13.       Ko, T. M. et al. Low neighborhood socioeconomic status is associated with poor outcomes in young adults with colorectal cancer. Surgery 176, 626–632 (2024). https://pubmed.ncbi.nlm.nih.gov/38972769/ 14.       Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A. & Jemal, A. Colorectal cancer statistics, 2023. CA. Cancer J. Clin. 73, 233–254 (2023). https://pubmed.ncbi.nlm.nih.gov/36856579/ 15.       Jain, S., Maque, J., Galoosian, A., Osuna-Garcia, A. & May, F. P. Optimal Strategies for Colorectal Cancer Screening. Curr. Treat. Options Oncol. 23, 474–493 (2022). https://pubmed.ncbi.nlm.nih.gov/35316477/ 16.       Zauber, A. G. The Impact of Screening on Colorectal Cancer Mortality and Incidence: Has It Really Made a Difference? Dig. Dis. Sci. 60, 681–691 (2015). https://pubmed.ncbi.nlm.nih.gov/25740556/ 17.       Edwards, B. K. et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116, 544–573 (2010). https://pubmed.ncbi.nlm.nih.gov/19998273/ 18.       Cercek, A. et al. Nonoperative Management of Mismatch Repair–Deficient Tumors. New England Journal of Medicine 392, 2297–2308 (2025). https://pubmed.ncbi.nlm.nih.gov/40293177/ 19.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Molecular Heterogeneity in Early-Onset Colorectal Cancer: Pathway-Specific Insights in High-Risk Populations. Cancers 17, 1325 (2025). https://pubmed.ncbi.nlm.nih.gov/40282501/ 20.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Ethnicity-Specific Molecular Alterations in MAPK and JAK/STAT Pathways in Early-Onset Colorectal Cancer. Cancers 17, 1093 (2025). https://pubmed.ncbi.nlm.nih.gov/40227607/ 21.       Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. JNCCN 19, 329–359 (2021). https://pubmed.ncbi.nlm.nih.gov/33724754/ 22.       Christenson, E. S. et al. Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancer. https://pubmed.ncbi.nlm.nih.gov/40388545/ 23.       Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. The Lancet 402, 41–53 (2023). https://pubmed.ncbi.nlm.nih.gov/37331369/ 24.       Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023). https://pubmed.ncbi.nlm.nih.gov/37142372/ 25.       Sauer, R. et al. Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. N. Engl. J. Med. 351, 1731–1740 (2004). https://pubmed.ncbi.nlm.nih.gov/15496622/ 26.       Cercek, A. et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol. 4, e180071 (2018). https://pubmed.ncbi.nlm.nih.gov/29566109/ 27.       Garcia-Aguilar, J. et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J. Clin. Oncol. 40, 2546–2556 (2022). https://pubmed.ncbi.nlm.nih.gov/35483010/ 28.       Schrag, D. et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N. Engl. J. Med. 389, 322–334 (2023). https://pubmed.ncbi.nlm.nih.gov/37272534/ 29.       Kunkler, I. H., Williams, L. J., Jack, W. J. L., Cameron, D. A. & Dixon, J. M. Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. N. Engl. J. Med. 388, 585–594 (2023). https://pubmed.ncbi.nlm.nih.gov/36791159/ 30.       Jacobsen, R. L., Macpherson, C. F., Pflugeisen, B. M. & Johnson, R. H. Care Experience, by Site of Care, for Adolescents and Young Adults With Cancer. JCO Oncol. Pract. (2021) doi:10.1200/OP.20.00840. https://pubmed.ncbi.nlm.nih.gov/33566700/ 31.       Ruddy, K. J. et al. Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer. J. Clin. Oncol. (2014) doi:10.1200/JCO.2013.52.8877. https://pubmed.ncbi.nlm.nih.gov/24567428/ 32.       Su, H. I. et al. Fertility Preservation in People With Cancer: ASCO Guideline Update. J. Clin. Oncol. 43, 1488–1515 (2025). https://pubmed.ncbi.nlm.nih.gov/40106739/ 33.       Smith, K. L., Gracia, C., Sokalska, A. & Moore, H. Advances in Fertility Preservation for Young Women With Cancer. Am. Soc. Clin. Oncol. Educ. Book 27–37 (2018) doi:10.1200/EDBK_208301. https://pubmed.ncbi.nlm.nih.gov/30231357/ 34.       Blumenfeld, Z. How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries. The Oncologist 12, 1044–1054 (2007). 35.       Bhagavath, B. The current and future state of surgery in reproductive endocrinology. Curr. Opin. Obstet. Gynecol. 34, 164 (2022). 36.       Ribeiro, R. et al. Uterine transposition: technique and a case report. Fertil. Steril. 108, 320-324.e1 (2017). 37.       Yazdani, A., Sweterlitsch, K. M., Kim, H., Flyckt, R. L. & Christianson, M. S. Surgical Innovations to Protect Fertility from Oncologic Pelvic Radiation Therapy: Ovarian Transposition and Uterine Fixation. J. Clin. Med. 13, 5577 (2024). 38.       Holowatyj, A. N., Eng, C. & Lewis, M. A. Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer. JCO Oncol. Pract. 18, 169–172 (2022). ***Behind the Knife Colorectal Surgery Oral Board Audio Review: https://app.behindtheknife.org/course-details/colorectal-surgery-oral-board-audio-review Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen